Drug Hunt

Cheap Drug Appears to Cut COVID Deaths By 30 Percent

"It's a major breakthrough."

6. 16. 20 / Victor Tangermann
Victor Tangermann
Image by Victor Tangermann

A drug used to reduce inflammation for a variety of conditions cuts the risk of death for COVID-19 patients on ventilators by a third, the BBC reports — an astonishing margin that could change the course of the world’s battle against the pandemic.

“This is the only drug so far that has been shown to reduce mortality — and it reduces it significantly,” Martin Landray, professor of medicine and epidemiology at Oxford and lead researcher, told the BBC. “It’s a major breakthrough.”

The drug, a low-dose steroid called dexamethasone, stops the body’s immune system from over-reacting and causing a “cytokine storm,” a common cause of death for patients who get seriously ill with COVID. For the same reason, the drug didn’t help those with milder symptoms, who didn’t require oxygen or a ventilator.

The drug trial, conducted by Oxford University, involved 2,000 hospital patients. They then compared the group to 4,000 other patients who did not take it.

Advertisement

In addition to the finding about patients on ventilators, the researchers found that for patients who require oxygen, the drug cut deaths by a fifth.

The cherry on top: the drug is cheap and widely available.

“There is a clear, clear benefit,” Landray added. “The treatment is up to 10 days of dexamethasone and it costs about £5 per patient. So essentially it costs £35 to save a life. This is a drug that is globally available.”

The news comes after the Food and Drug Administration pulled emergency authorization for the use of the antimalaria drug hydroxychloroquine on Monday to treat the coronavirus, in light of troubling trial results, some of which showed the drug may actually do more harm than good.

Advertisement

The effectiveness of a different antiviral, called remdesivir, has also been called into question by the FDA after it was touted by White House health advisor Anthony Fauci as a promising COVID-19 treatment in April. On Monday, the agency warned healthcare providers that the drug shouldn’t be used in combination with hydroxychloroquine. In early May, the FDA granted emergency use of remdesivir for COVID-19 patients.

There’s still plenty of work to be done before we can call dexamethasone a standard treatment plan for severe cases of COVID-19 — but early results look promising.


As a Futurism reader, we invite you join the Singularity Global Community, our parent company’s forum to discuss futuristic science & technology with like-minded people from all over the world. It’s free to join, sign up now!

Advertisement

Copyright ©, Singularity Education Group All Rights Reserved. See our User Agreement, Privacy Policy and Cookie Statement. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with prior written permission of Futurism. Fonts by Typekit and Monotype.